Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06261957 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 477
- Enrollment target
NCT06261957 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 477 participants.
The verdict
NCT06261957, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 477 participants
- Enrollment target
Study Summary
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
Interventions
- DRUG Salbutamol HFA-134a
- DRUG Salbutamol HFA-152a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06261957
The ClinicalTrials.gov registry entry for NCT06261957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 477 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Salbutamol HFA-134a is the first listed.
NCT06261957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06261957 about?
NCT06261957 is a clinical study titled "A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma". The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
What is the current status of trial NCT06261957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 477 participants. The study started on 2024-05-31. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT06261957?
The interventions under investigation include: Salbutamol HFA-134a (DRUG), Salbutamol HFA-152a (DRUG).
Who is sponsoring clinical trial NCT06261957?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.